A groundbreaking clinical trial conducted in India has revealed a simple yet powerful strategy to significantly reduce early deaths in children with leukemia. The study, led by the Indian Childhood Collaborative Leukaemia (ICiCle) group, including researchers from the University of Manchester, has found that administering steroids in short bursts, rather than continuously, can halve early treatment-related deaths without compromising the chances of a cure. This discovery is particularly impactful for low- and middle-income countries, where early deaths during treatment are a major concern, often due to severe infections linked to continuous steroid use.
The trial, published in the Lancet Regional Health - Southeast Asia, involved over 3000 children with acute B-cell precursor acute lymphoblastic leukaemia (ALL) at six major centers across India. The researchers compared the standard four-week continuous steroid course with a pulsed schedule given in weeks one, two, and four. The results were remarkable: children on the pulsed schedule experienced a significant reduction in early deaths, from 3.5% to 1.3%.
This finding is crucial because it addresses a critical challenge in low- and middle-income countries, where infections are a leading cause of early deaths during leukemia treatment. By reducing the continuous exposure to steroids, the risk of severe infections is minimized without sacrificing the treatment's effectiveness. Remission rates remained high at around 98% in both groups, and survival outcomes were similar, indicating that this safer approach does not compromise the cure.
The study also uncovered an interesting insight: the use of powerful chemotherapy drugs called anthracyclines early in treatment increased the risk of treatment-related deaths. This finding highlights the importance of careful treatment planning and the potential benefits of alternative drug regimens. The ICiCle-ALL-14 trial, the first multicenter randomized paediatric oncology trial conducted in India, has provided valuable evidence that steroid scheduling is a modifiable factor in induction mortality.
The implications of this research are far-reaching. Professor Vaskar Saha, the lead author and founder of the ICiCle group, emphasizes the practicality and cost-effectiveness of this intervention, suggesting that it could be widely adopted in settings where treatment-related mortality remains high. This simple change in steroid administration could save countless lives and improve treatment outcomes for children with leukemia in low- and middle-income countries.
The study's funding support from various organizations, including the National Cancer Grid and the Indian Council of Medical Research, underscores the importance and potential impact of this research. The participating centers, located across India, demonstrate the collaborative effort to bring modern treatment approaches to children with leukemia. This trial not only highlights a potential solution to a critical problem but also opens up new avenues for research and treatment innovation in paediatric oncology.
